Peter Jensen, MD | ARUP Laboratories

Peter Jensen, MD

Peter Jensen, MD

Chairman, Board of Directors, ARUP Presidential Endowed Chair

Professor and Chair of the Department of Pathology, University of Utah School of Medicine

Education

Medical Degree—Vanderbilt University
Internship—Pathology, Barnes-Jewish Hospital
Residency—Pathology, Barnes-Jewish Hospital

Certification/Affiliations

American Board of Pathology
President-Elect, President, Past-President, Association of Pathology Chairs
Chairman, Board of Directors, ARUP Laboratories
Chair, AAI Committee on Public Affairs
APC Exploratory Development Committee
APC Research Committee

Research Interests

Healthcare transformation
Precision diagnostics
Application of new technology in pathology and laboratory medicine
Antigen processing and presentation
MHC molecules in regulating immune responses
Type 1 diabetes/autoimmunity
Cancer immunotherapy

Awards

Summa Cum Laude, 1977
Elected to American Society for Clinical Investigation, 1996
Deans Clinical Investigator Award, 2000, 2002
NIH MERIT Award, 2001
CAP President’s Honors Award, 2011
Distinguished Fellow of the American Association of Immunologists, 2020

Recent Publications

Ghosh D, et al. Regulation of the BCR signalosome by the class II peptide editor, H2-M, affects the development and repertoire of innate-like B cells. Cell Rep. 2022;38(4):110200.
Bailey DN, et al. Generating discretionary income in an academic department of pathology. Acad Pathol. 2021;8:23742895211044811.
Kim H, et al. Targeting transcriptional coregulator OCA-B/Pou2af1 blocks activated autoreactive T cells in the pancreas and type 1 diabetes. J Exp Med. 2021;218(3):e20200533.
Reyes-Vargas E, et al. HLA-DM catalytically enhances peptide dissociation by sensing peptide-MHC class II interactions throughout the peptide-binding cleft. J Biol Chem. 2020;295(10):2959–73.
Xiao H, et al. Elimination of osteosarcoma by necroptosis with graphene oxide-associated anti-HER2 antibodies. Int J Mol Sci. 2019;20(18):4360.
Zhou Z, et al. Peptidomic analysis of type 1 diabetes associated HLA-DQ molecules and the impact of HLA-DM on peptide repertoire editing. Eur J Immunol. 2017;47:314–26.